EHAB vs. AHCO, AVAH, CHE, OPCH, AMED, ADUS, BTSG, CPRX, AMPH, and NMRA
Should you be buying Enhabit stock or one of its competitors? The main competitors of Enhabit include AdaptHealth (AHCO), Aveanna Healthcare (AVAH), Chemed (CHE), Option Care Health (OPCH), Amedisys (AMED), Addus HomeCare (ADUS), BrightSpring Health Services (BTSG), Catalyst Pharmaceuticals (CPRX), Amphastar Pharmaceuticals (AMPH), and Neumora Therapeutics (NMRA). These companies are all part of the "medical" sector.
AdaptHealth (NASDAQ:AHCO) and Enhabit (NYSE:EHAB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, community ranking, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.
In the previous week, AdaptHealth had 1 more articles in the media than Enhabit. MarketBeat recorded 8 mentions for AdaptHealth and 7 mentions for Enhabit. Enhabit's average media sentiment score of 0.76 beat AdaptHealth's score of 0.40 indicating that AdaptHealth is being referred to more favorably in the media.
AdaptHealth received 74 more outperform votes than Enhabit when rated by MarketBeat users. Likewise, 59.23% of users gave AdaptHealth an outperform vote while only 11.54% of users gave Enhabit an outperform vote.
82.7% of AdaptHealth shares are owned by institutional investors. 4.4% of AdaptHealth shares are owned by insiders. Comparatively, 1.9% of Enhabit shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Enhabit has a net margin of -7.95% compared to Enhabit's net margin of -21.45%. Enhabit's return on equity of 8.47% beat AdaptHealth's return on equity.
AdaptHealth presently has a consensus target price of $10.70, suggesting a potential downside of 4.63%. Enhabit has a consensus target price of $9.79, suggesting a potential downside of 5.49%. Given Enhabit's stronger consensus rating and higher possible upside, equities analysts clearly believe AdaptHealth is more favorable than Enhabit.
Enhabit has lower revenue, but higher earnings than AdaptHealth. Enhabit is trading at a lower price-to-earnings ratio than AdaptHealth, indicating that it is currently the more affordable of the two stocks.
AdaptHealth has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, Enhabit has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500.
Summary
AdaptHealth beats Enhabit on 13 of the 18 factors compared between the two stocks.
Get Enhabit News Delivered to You Automatically
Sign up to receive the latest news and ratings for EHAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EHAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
Free EHAB Stock Alerts